| Literature DB >> 31642193 |
Pablo D Moço1, Noga Aharony1, Amine Kamen1.
Abstract
Immunotherapy with T cells expressing chimeric antigen receptors (CAR) is an emerging and promising treatment against refractory cancers. However, the currently adopted methods of modification of T cells pose a risk of insertional oncogenesis because lentiviral and retroviral vectors integrate the CAR transgene in a semi-random fashion. In addition, this therapy is only available using autologous cells, which create problems in production and limit the access for patients who have their T cells depleted. One modification method that shows the ability to overcome both drawbacks is the knock-in of the CAR simultaneously knocking-out genes that prevent allogeneic therapy, such as the endogenous T cell receptor. In this mini-review, the authors present recent efforts to develop safer universal CAR-T cells. More specifically, the combined application of target-directed nucleases, which create a double-strand break at a specific genome locus, and the delivery of CAR DNA via adeno-associated viral vectors for subsequent integration via homologous recombination and silencing of the targeted gene is focused on.Entities:
Keywords: CRISPR/Cas9; adeno-associated virus; chimeric antigen receptor-T cells; homologous recombination; nuclease; transcription activator like effector nuclease; zinc-finger
Mesh:
Substances:
Year: 2019 PMID: 31642193 DOI: 10.1002/biot.201900286
Source DB: PubMed Journal: Biotechnol J ISSN: 1860-6768 Impact factor: 4.677